EUVIMEDEUVIMED entdecken
Open Access

PD-1 engagement and circulating Th17 effector activity during secukinumab treatment in plaque psoriasis

Mengmeng Zhang, Xujiao Feng, Kexiang Yan, Jiaqing Zhou, Lei Shen, Zhenghua Zhang iD

Clinical and Experimental Immunology · 06.01.2026 · 220 (1)

DOI: 10.1093/cei/uxag037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 30.06.2026. Verfasst von Mengmeng Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Huashan Hospital Fudan University, Shanghai Institute of Dermatology, Shanghai, China. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Psoriasis, Antibodies, Monoclonal, Humanized, Th17 Cells. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plaque psoriasis (PP) is a chronic immune-mediated inflammatory disease driven by dysregulation of the IL-23/Th17/IL-17 axis. Although IL-17A-targeted biologics achieve robust clinical efficacy, the systemic immune remodeling accompanying successful treatment remains incompletely understood. We performed longitudinal immune profiling in seven patients with PP before treatment and after achieving a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) following secukinumab therapy. Circulating T-cell subsets, programmed cell death protein 1 (PD-1)-expressing populations, cutaneous lymphocyte antigen-positive (CLA+) T cells, and plasma cytokines were analyzed by flow cytometry and multiplex assays. Ex vivo responses to the PD-1 agonist peresolimab were further evaluated in an independent cohort. At baseline, patients exhibited reduced frequencies of regulatory T cells compared with healthy controls. Following PASI 90, circulating Th17 and Th2 cell frequencies increased despite minimal sustained changes in plasma cytokine levels, suggesting dissociation between effector T-cell expansion and soluble inflammatory mediators during IL-17A blockade. Circulating CD4+CLA+ T cells were partially restored, and treatment was accompanied by increased frequencies of PD-1-expressing CD4+ T-cell subsets, which were inversely associated with disease activity over time. Ex vivo PD-1 engagement selectively suppressed IL-17A-producing CD4+ T cells while largely preserving IFN-γ production. These findings suggest that clinical improvement during IL-17A blockade is accompanied by coordinated immune remodeling rather than generalized systemic immunosuppression and that PD-1 signaling may contribute to restraining Th17 effector function during therapeutic response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorPsoriasisAntibodies, Monoclonal, HumanizedTh17 CellsAntibodies, MonoclonalHumansFemaleMaleMiddle AgedAdultInterleukin-17CytokinesT-Lymphocytes, Regulatory

Stichwörter der Autor:innen

PD-1Th17peresolimabplaque psoriasissecukinumab

Substanzen

Programmed Cell Death 1 ReceptorAntibodies, Monoclonal, HumanizedsecukinumabInterleukin-17PDCD1 protein, humanAntibodies, MonoclonalCytokines

Autor:innen und Institutionen

  • Department of Dermatology, Huashan Hospital Fudan University, Shanghai Institute of Dermatology, Shanghai, China.
  • Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Dermatology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Dermatology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Zhenghua Zhang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, M., Feng, X., Yan, K., Zhou, J., Shen, L., & Zhang, Z. (2026). PD-1 engagement and circulating Th17 effector activity during secukinumab treatment in plaque psoriasis. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag037

Vancouver

Zhang M, Feng X, Yan K, Zhou J, Shen L, Zhang Z. PD-1 engagement and circulating Th17 effector activity during secukinumab treatment in plaque psoriasis. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag037

BibTeX
@article{Zhang2026,
  author = {Zhang, Mengmeng and Feng, Xujiao and Yan, Kexiang and Zhou, Jiaqing and Shen, Lei and Zhang, Zhenghua},
  title = {PD-1 engagement and circulating Th17 effector activity during secukinumab treatment in plaque psoriasis},
  journal = {Clinical and Experimental Immunology},
  year = {2026},
  volume = {220},
  number = {1},
  doi = {10.1093/cei/uxag037}
}
Kostenlos starten →